Identification of a novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human influenza virus and a corresponding viral escape mutation

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved..

The influenza A virus (IAV) NS1 protein is one of the major regulators of pathogenicity, being able to suppress innate immune response and host protein synthesis. In this study we identified the human micro RNA hsa-miR-1307-3p as a novel potent suppressor of NS1 expression and influenza virus replication. Transcriptomic analysis indicates that hsa-miR-1307-3p also negatively regulates apoptosis and promotes cell proliferation. In addition, we identified a novel mutation in the NS1 gene of A(H1N1)pdm09 strains circulating in Italy in the 2010-11 season, which enabled the virus to escape the hsa-miR-1307-3p inhibition, conferring replicative advantage to the virus in human cells. To the best of our knowledge, this is the first validation of suppression of IAV H1N1 NS1 by a human micro RNA and the first example of an escape mutation from micro RNA-mediated antiviral response for the A(H1N1)pdm09 virus.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:171

Enthalten in:

Antiviral research - 171(2019) vom: 01. Nov., Seite 104593

Sprache:

Englisch

Beteiligte Personen:

Bavagnoli, Laura [VerfasserIn]
Campanini, Giulia [VerfasserIn]
Forte, Maurizio [VerfasserIn]
Ceccotti, Giorgia [VerfasserIn]
Percivalle, Elena [VerfasserIn]
Bione, Silvia [VerfasserIn]
Lisa, Antonella [VerfasserIn]
Baldanti, Fausto [VerfasserIn]
Maga, Giovanni [VerfasserIn]

Links:

Volltext

Themen:

3' Untranslated Regions
Antiviral micro-RNA
Escape mutation
Host-pathogen interaction
Human influenza a virus
INS1 protein, influenza virus
Influenza pandemics
Journal Article
MicroRNAs
RNA, Viral
Research Support, Non-U.S. Gov't
Viral Nonstructural Proteins

Anmerkungen:

Date Completed 08.07.2020

Date Revised 08.07.2020

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.antiviral.2019.104593

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM300793510